Cargando…
Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
Migraine is one of the most disabling disorders in the world, associated with poor quality of life. Migraine prevention strategies have increasingly evolved since monoclonal antibodies against the calcitonin gene-related peptide (CGRP), or its receptor, were identified. CGRP is the ideal target of m...
Autores principales: | Torrisi, Michele, Corallo, Francesco, Lo Buono, Viviana, Di Cara, Marcella, Grugno, Rosario, Lo Presti, Riccardo, Quartarone, Angelo, De Cola, Maria Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222452/ https://www.ncbi.nlm.nih.gov/pubmed/37241168 http://dx.doi.org/10.3390/medicina59050936 |
Ejemplares similares
-
Functional connectivity and cognitive impairment in migraine with and without aura
por: Lo Buono, Viviana, et al.
Publicado: (2017) -
Body Image and Emotional Status in Patients with Acquired Brain Injury
por: Lo Buono, Viviana, et al.
Publicado: (2023) -
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
por: Pilati, Laura, et al.
Publicado: (2023) -
The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020) -
Multisensory stimulation and rehabilitation for disability improvement: Lessons from a case report
por: Lo Buono, Viviana, et al.
Publicado: (2022)